Veronica Tkachuk
Overview
Explore the profile of Veronica Tkachuk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Recommendations on NMOSD treatment in Latin America: Utilizing consensus-based RAND/UCLA methodology
Alonso R, Rivera V, Carnero Contentti E, Hamuy Diaz de Bedoya V, Ciampi E, Silva B, et al.
Mult Scler Relat Disord
. 2025 Jan;
94:106244.
PMID: 39823690
Introduction: Neuromyelitis optica spectrum disorder (NMOSD) is a serious condition affecting people worldwide, including Latin America (LATAM). Healthcare disparities and economic limitations make effective treatment access challenging. It is crucial...
2.
Carnero Contentti E, Pestchanker C, Ciampi E, Castro Suarez S, Caparo Zamalloa C, Daccach Marques V, et al.
Eur J Neurol
. 2024 Sep;
31(12):e16445.
PMID: 39287067
Background And Purpose: The diagnostic criteria for myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-associated disease (MOGAD) were published in 2023. We aimed to determine the performance of the new criteria in Latin...
3.
Silva B, Heriz A, Ayerbe J, Lazaro L, Casas M, Lopez P, et al.
Neurol Sci
. 2024 Sep;
45(12):5841-5848.
PMID: 39259243
Introduction: Cladribine was approved for Multiple Sclerosis (MS) in our country in 2018. A previous study by our group showed that its use among high efficacy therapies options has been...
4.
Silva B, Miglietta E, Casabona J, Wenker S, Eizaguirre M, Alonso R, et al.
Front Immunol
. 2024 Sep;
15:1431403.
PMID: 39224589
Introduction: There are no reports in LATAM related to longitudinal humoral and cellular response to adenovirus based COVID-19 vaccines in people with Multiple Sclerosis (pwMS) under different disease modifying therapies...
5.
Carnero Contentti E, Alonso R, Silva B, Burgos M, Tavolini D, Lopez P, et al.
Neurol Sci
. 2024 Jul;
45(12):5833-5840.
PMID: 39080156
Background: We assessed the effectiveness, safety and patient-reported outcomes (PROs) of dimethyl fumarate (DMF) in real-world clinical practice in patients with multiple sclerosis (PwMS) from Argentina. Methods: We conducted a...
6.
Marrodan M, Calandri I, Bocancea D, Ysrraelit M, Gomez Figueroa E, Masso Paez M, et al.
Ann Neurol
. 2024 Jul;
96(5):846-854.
PMID: 39056308
Objective: Susac syndrome (SuS), multiple sclerosis (MS), and primary angiitis of the central nervous system (PACNS) present diagnostic challenges due to overlapping clinical features. We aimed to enhance diagnostic precision...
7.
Carnero Contentti E, Lopez P, Patrucco L, Cristiano E, Miguez J, Silva B, et al.
Mult Scler Relat Disord
. 2024 Jul;
89():105771.
PMID: 39033591
Background: Immunosuppressive therapies as azathioprine (AZA), mycophenolate mofetil (MMF) and rituximab (RTX) are widely prescribed as first-line treatment to prevent relapses in NMOSD. However, the rate of response to these...
8.
Rojas J, Alonso R, Luetic G, Patrucco L, Casas M, Silva B, et al.
Clin Neuropharmacol
. 2024 Jul;
47(4):120-127.
PMID: 39008542
Objective: The aim was to evaluate patient profiles, effectiveness and safety of cladribine (CLAD) in patients with relapsing-remitting multiple sclerosis in Argentina. Methods: This was a substudy included in RelevarEM...
9.
Carnero Contentti E, Lopez P, Pettinicchi J, Miguez J, Patrucco L, Cristiano E, et al.
J Neurol Sci
. 2024 Jun;
462:123099.
PMID: 38897155
Methods: We conducted a retrospective study involving NMOSD patients from the Argentinean MS and NMOSD registry (RelevarEM, NCT03375177). Treatment response at 6 months was categorized as "good" if the EDSS...
10.
Piedrabuena M, Correale J, Fiol M, Marrodan M, Rojas J, Alonso M, et al.
J Neurol Sci
. 2024 May;
461:123052.
PMID: 38797140
Background: Knowledge of the safety and efficacy of disease-modifying therapies (DMTs) in older patients with Multiple Sclerosis (pwMS) is limited due to their exclusion from clinical trials. Our purpose is...